Aplastic anemia successfully treated with rituximab: The possible role of aplastic anemia-associated autoantibodies as a marker for response

• Takamatsu, Hiroyuki

• Yagasaki, Hiroshi

• Takahashi, Yoshiyuki

• Hama, Asahito

• Saikawa, Yutaka

• Yachie, Akihiro

• Koizumi, Shoichi

• Kojima, Seiji

• Nakao, Shinji

抄録

金沢大学医薬保健研究域医学系

A 1-yr-old Japanese male infant developed hepatitis-associated aplastic anemia (AA), and anti-thymocyte globulin (ATG) plus cyclosporine A (CsA) was administered without any appreciable effects. Laboratory examination of the patient's serum obtained before therapy revealed various autoantibodies, such as PA-IgG, anti-platelets, anti-single-stranded DNA (ssDNA), and anti-double-stranded DNA (dsDNA) antibodies (Abs) in addition to anti-DRS-1 Abs and anti-moesin Abs, both of which are known to be detectable in approximately 40% of all patients presenting with AA. He was therefore treated with 17.5mg/kg/d rituximab 5.5months after ATG/CsA therapy. The same rituximab therapy was repeated three times once a month thereafter. His neutrophil counts started to increase 50d after the first rituximab therapy and he achieved a complete remission at 16months after the last rituximab administration. All of the autoantibodies including anti-ssDNA, dsDNA, DRS-1, and moesin became undetectable when he attained the remission. Anti-CD20 monoclonal antibody therapy may be effective in a subset of patients with AA characterized by the presence of autoantibodies. © 2011 John Wiley & Sons A/S.

収録刊行物

• European Journal of Haematology

  European Journal of Haematology 86 (6), 541-545, 2011-06-01

  Wiley-Blackwell

キーワード

• Aplastic anemia
• Autoantibody
• Rituximab

詳細情報

• CRID: 1050282810930466688
• NII論文ID: 120003141908
• NII書誌ID: AA10668976
• ISSN: 09024441
• Web Site: http://hdl.handle.net/2297/28340
• 本文言語コード: en
• 資料種別: journal article
• データソース種別:
  • IRDB
  • CiNii Articles